MiNK Therapeutics
INKT
34 hedge funds and large institutions have $800K invested in MiNK Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 7 closing their positions.
0.22% less ownership
Funds ownership: 0.43% → 0.21% (-0.22%)
19% less funds holding
Funds holding: 42 → 34 (-8)
56% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 16
74% less capital invested
Capital invested by funds: $3.1M → $800K (-$2.3M)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$36.2K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$3.16K |
| 3 |
C
Covestor
London,
United Kingdom
|
+$814 |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$651 |
| 5 |
Goldman Sachs
New York
|
+$488 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$682K |
| 2 |
AG
Artal Group
Luxembourg
|
-$368K |
| 3 |
Renaissance Technologies
New York
|
-$143K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$107K |
| 5 |
VF
Virtu Financial
New York
|
-$30K |
INKT Hedge Fund Activity: Q3 2023 in Review
34 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q3 2023, worth a combined $800K — down 74% from $3.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of INKT and 1 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 7 added.
The largest buyer was CAPTRUST Financial Advisors, adding an estimated $36.2K. The largest seller was Deep Track Capital, exiting entirely with an estimated $682K sold.
- 34 institutional investors held MiNK Therapeutics (INKT) as of Q3 2023, down from 42 in Q2 2023.
- Funds reported $800K of MiNK Therapeutics stock for Q3 2023, down 74% quarter-over-quarter.
- 1 fund opened new MiNK Therapeutics positions in Q3 2023 and 7 closed out, a net change of -6 holders.
- The largest MiNK Therapeutics buyer in Q3 2023 was CAPTRUST Financial Advisors, an estimated $36.2K added.
- The largest MiNK Therapeutics seller in Q3 2023 was Deep Track Capital, an estimated $682K sold.
Based on aggregated 13F filings for Q3 2023.